Literature DB >> 10455257

Inhibition of gelatinase activity in human airway epithelial cells and fibroblasts by dexamethasone and beclomethasone.

J E Carver1, W A Galloway, C Robinson.   

Abstract

The effects of dexamethasone and beclomethasone on gelatinase activity released from lung epithelial cells (A549, NCI-H292 and Calu-3 cell lines and NHBE primary cultures) and human lung fibroblasts (HLF) were investigated. All cells spontaneously released gelatin-degrading activity but the amounts were unaffected by treatment with glucocorticoids. Phorbol myristate acetate (PMA) increased the amount of gelatinase activity in conditioned media prepared from all cell types examined. In epithelial cells, PMA induced the expression of gelatinase B, whereas in HLF the increased gelatinase activity resulted from increased activation of gelatinase A. Dexamethasone and beclomethasone produced concentration-dependent inhibition of PMA-induced gelatinase activity in HLF and epithelial cell lines. In the epithelial cell lines, the inhibition of activity was associated with an attenuation of enzyme induction by PMA. In contrast, primary cultures of human bronchial epithelial cells were unresponsive to dexamethasone at concentrations that were maximally effective at inhibiting gelatinase activity induced in other cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455257      PMCID: PMC1566123          DOI: 10.1038/sj.bjp.0702650

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP).

Authors:  G Murphy; M I Cockett; R V Ward; A J Docherty
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

2.  In vitro modulation of the eosinophil-dependent enhancement of the permeability of the bronchial mucosa.

Authors:  C A Herbert; D Edwards; J R Boot; C Robinson
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

3.  The AP-1 sequence is necessary but not sufficient for phorbol induction of collagenase in fibroblasts.

Authors:  D T Auble; C E Brinckerhoff
Journal:  Biochemistry       Date:  1991-05-07       Impact factor: 3.162

4.  Positive and negative transcriptional elements of the human type IV collagenase gene.

Authors:  S M Frisch; J H Morisaki
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

5.  Similar effects of adenovirus E1A and glucocorticoid hormones on the expression of the metalloprotease stromelysin.

Authors:  R Offringa; A M Smits; A Houweling; J L Bos; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

6.  Interleukin-1 stimulates and all-trans-retinoic acid inhibits collagenase gene expression through its 5' activator protein-1-binding site.

Authors:  R Lafyatis; S J Kim; P Angel; A B Roberts; M B Sporn; M Karin; R L Wilder
Journal:  Mol Endocrinol       Date:  1990-07

Review 7.  Positive and negative regulation of collagenase gene expression.

Authors:  C Jonat; B Stein; H Ponta; P Herrlich; H J Rahmsdorf
Journal:  Matrix Suppl       Date:  1992

8.  Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site.

Authors:  R C Nicholson; S Mader; S Nagpal; M Leid; C Rochette-Egly; P Chambon
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

9.  The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites.

Authors:  A Gutman; B Wasylyk
Journal:  EMBO J       Date:  1990-07       Impact factor: 11.598

10.  Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation in vivo.

Authors:  H König; H Ponta; H J Rahmsdorf; P Herrlich
Journal:  EMBO J       Date:  1992-06       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.